According to the report, the joint pain injections market size is expected to reach US$ 11 billion by 2030 and is expanding at a CAGR of 8.5 from 2021 to 2030.
Rise in number of geriatric patients, increase in awareness regarding joint disorders, and high unmet medical needs are expected to augment the global market. The joint pain injections market is projected to expand, owing to an increase in the prevalence of joint pain among the population, demand for better treatments, and development of healthcare infrastructure in various countries across the globe. The rise in the prevalence of arthritis and musculoskeletal disorders is driving the demand for joint pain injections usage, especially among the population aged 65 years or older as they are more prone to joint pains.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38754
Report Scope of the Joint Pain Injections Market
|Market Size||US$ 11 Billion by 2030|
|Growth Rate||CAGR of 8.5% From 2021 to 2030|
|Forecast Period||2021 to 2030|
|Largest Market||North America|
|Fastest Growing Market||Asia Pacific|
|Companies Mentioned||Allergan Plc., Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Flexion Therapeutics, Inc., Zimmer Biomet Holdings, Inc., SEIKAGAKU CORPORATION, and Chugai Pharmaceutical Co., Ltd.|
SYNOJOYNT Receives FDA Approval
Joint pain injections are available for include hip, knee and ankle, shoulder and elbow joints. Of these, knee and ankle joints hold the largest share in the global market. This will surge the joint pain injections market size in the forthcoming years. These injections effectively reduce inflammation and pain in knees, thus increasing their demand.
“The increasing demand for cost-effective treatments and the rising prevalence of osteoarthritis are driving the joint pain injections market,” stated a lead analyst at Fortune Business Insights. These, coupled with rising technological advancements in healthcare, are likely to uplift the market growth. Several companies are introducing new products to strengthen their market position. SYNOJOYNT, a joint pain injection receives FDA approval for marketing this product. The injection was introduced by TEVA Pharmaceuticals in May 2018 for patients suffering from osteoarthritis. Zimmer Biomet develops a new joint pain injection containing hydraulic acid called Gel-One Hyaluronate. The injection received FDA approval in February 2017 and is used to treat patients with knee osteoarthritis.
Increasing prevalence of arthritis and other bone-related disorders
According to facts published by Arthritis Foundation, arthritis is the leading cause of disability among adults in the U.S. Approximately 54 million adults and 300,000 babies and children in the U.S. suffer from arthritis or any rheumatic condition. More than 78 million people in the U.S. are likely to suffer from doctor-diagnosed arthritis by 2040. Furthermore, osteoarthritis is the most common type of arthritis and affects approximately 31 million people in the U.S. Increasing prevalence of arthritis further boosts the demand for disease modifying treatments, which in turn is anticipated to propel the joint pain injections market during forecast period.
Increase in prevalence of obesity leading to joint pain
Obesity is considered a risk factor for various joint disorders, especially related to knee, such as knee pain and knee osteoarthritis. According to the fact sheet published by World Health Organization (WHO), worldwide obesity has tripled since 1975. In 2016. 1.9 billion people were overweight and among them, more than 650 million adults were obese. Moreover, approximately 41 million children under the age of 5 were obese in 2016. According to the 2015-2016 National Health and Nutrition Examination Survey (NHANES), more than one in four children of Hispanic origin ages 2 to 19 had obesity, and approximately 47% of adults suffered from obesity. Increasing patient pool in developing countries as well as developed countries is estimated to propel healthcare spending for joint pain treatments in these countries and consequently, drive the joint pain injections market.
High unmet needs in patients with joint pain
Arthritis is the most common cause of joint pain and a major cause of disability and impaired mobility among the population. Currently available treatment options are insufficient, as they primarily focus on symptom relief and pain mitigation. There are no drugs available that can cure, reverse, or halt disease progression such as osteoarthritis. Moreover, some patients are unable to find relief with available treatments and continue to suffer in pain; therefore, there are large unmet needs in patients with joint pain. This provides opportunity for advance treatment options in the joint pain injections market.
Hyaluronic acid injections segment dominates the global market due to increasing acceptance for the treatment of osteoarthritis
In terms of injection type, hyaluronic acid injections is a highly attractive segment of the global joint pain injections market, followed by corticosteroid injections and others segments. This is attributable to the effectiveness of hyaluronic acid injections in the treatment of knee osteoarthritis, where other treatments are contraindicated. According to rapid response report published by CADTH, viscosupplementation with hyaluronic acid in adults with knee osteoarthritis is superior to intra-articular placebo and other conventional medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), in terms of improving knee pain and function with minimum adverse effects.
North America dominates the global market owing to high acceptance of viscosupplementation in the region
North America dominates the global joint pain injections market due to a large patient pool, increase in the geriatric population, increased obesity, and high acceptance of advanced treatments for the joint pain relief in the region. The region is estimated to maintain its dominance during the forecast period. Viscosupplementation with hyaluronic acid products is approved by US FDA for the treatment of knee osteoarthritis. Moreover, rising healthcare expenditure and increasing investments are key factors that are anticipated to boost the joint pain injections market in the next few years.
The market in Asia Pacific is expected to witness considerable growth owing to the rising prevalence of joint disorders and patient pool. Several government organizations are conducting awareness programs on different types of arthritis treatments available in the region. This will enhance the quality of life for such patients and augment demand for joint pain injections. Influenced by these factors, the joint pain infections market size is estimated to grow over the projected horizon.
Joint Pain Injections Market key players
Major players operating in the joint pain injections market include Allergan Plc., Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Flexion Therapeutics, Inc., Zimmer Biomet Holdings, Inc., SEIKAGAKU CORPORATION, and Chugai Pharmaceutical Co., Ltd.
Read also @ Urology Devices Market Size, Trends And Forecast To 2030
Joint Pain Injections Market Segmentation
By Injection Type
- Corticosteroid Injections
- Hyaluronic Acid Injections
By Joint Type
- Knee & Ankle
- Hip Joint
- Shoulder & Elbow
- Facet Joints of the Spine
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38754
Vision Research Reports
Call: +1 9197 992 333
Email: [email protected]